Antibodies for Parkinson's Disease Targets

Key disease targets of Parkinson's disease can be found with rabbit monoclonal antibodies.

​​​​To provide the tools needed for Parkinson’s disease research, Abcam partnered with the Michael J. Fox Foundation to develop rabbit monoclonal antibodies for RAB8A, RAB10 alpha-synuclein, DJ-1, and leucine-rich repeat kinase 2 (LRRK2).

The Michael J. Fox Foundation

The Michael J. Fox Foundation is concerned with finding a cure for Parkinson's disease through an impressively funded research program, and with ensuring the improvement of therapies for those living with the disease today.

LRRK2

Gene mutation of LRRK2 is the most common inherited cause of Parkinson's disease. Though it is the focus of intensive research in the Parkinson's field, a lack of LRRK2 antibodies of high-quality has been a major hurdle to the successful development of LRRK2-based therapies.

After primary characterization organized by MJFF, and feedback from the Parkinson’s disease research community, the three best performing rabbit monoclonal clones exhibited were selected for distribution by Abcam.​

LRRK2 antibodies are critical to help move Parkinson's research forward. The three unique clones chosen for initial release were identified based on several months of testing by our large network of PD researchers... we are excited that they [Abcam] will continue to help MJFF remove barriers to developing Parkinson's therapies.

Dr. Mark Frasier, Vice President of Research Programs at MJFF

LRRK2 Antibodies

Antibody name Clone ID Applications Species AbID
LRRK2 MJFF2
(c41-2)
ICC/IF, IHC-FrFl, IHC-P,
IP, WB
Hu, Ms,
Rt
ab133474
LRRK2 MJFF3
(c69-6)
ICC/IF, IHC-P, IP, WB Hu, Ms,
Rt
ab133475
LRRK2 MJFF4
(c81-8)
ICC/IF, IHC-P, IP, WB Hu, Ms,
Rt
ab133476
LRRK2 MJFF5 (68-7) WB Hu, Ms ab181386
LRRK2 UDD3 30(12) ICC/IF, IHC-P, WB Hu, Ms ab133518
LRRK2
(phospho S910)
UDD1 15(3) WB Hu ab133449
LRRK2
(phospho S935)
UDD2 10(12) ICC/IF, WB Hu, Ms ab133450
LRRK2 (phospho S955) MJF-R11 (75-1) WB Hu, Ms ab169521
LRRK2 (phospho S973) MJF-R12 (37-1) WB Hu ab181364
LRRK2 (phospho T1410) MJFR4-25-5 WB Hu, Ms,
Rt
ab140107
LRRK2
(phospho T1491)
MJFR5-88-3 WB Hu ab140106
LRRK2 (phospho T1503) MJF-R6
(227-1a)
WB Hu ab154423
LRRK2 (phospho S1292) MJFR-19-7-8 WB Hu ab203181
LRRK2 (phospho T2483) MJF-R8
(21-2e)
WB Hu ab156577

 

Alpha-Synuclein

The first gene to be linked to Parkinson’s disease, Alpha-synuclein, is the most promising link to PD pathogenesis. A major feature of PD pathology are Lewy bodies, of which Alpha-synuclein is a major component.

Synuclein Antibodies

Antibody name Clone ID Applications Species AbID
Alpha-synuclein MJFR1 ELISA, Flow Cyt, ICC/IF, IHC-P, IP, WB Hu, Drosophila melanogaster ab138501
Alpha-synuclein (phospho S129) MJF-R13
(8-8)
WB Hu ab168381
Alpha synuclein filament - conformation specific MJFR-14-6-4-2 ICC/IF, IHC-P, dot blot Hu, Ms, Rt ab209538

 

DJ-1

DJ-1 (PARK7) is thought to act as a sensor of oxidative stress in cells, and has increasingly been investigated for modifications that occur as a result of disease pathogenesis, including protein oxidation.

DJ-1 Antibody

Antibody name Clone ID Application Species AbID
DJ1 (PARK7) MJF-R16
(66-5)
WB Hu ab169520

 

Rab8A and Rab10

Inherited early-onset Parkinson's disease is caused by, rarely, impairment of certain Rab GTPases (Rabs) that modulate α-synuclein. Rab8 and Rab10 aid in trafficking glucose transporter type 4 (GLUT4) to the plasma membrane, specifically.

Rab Antibodies

Antibody name Clone ID Application Species AbID
Anti-RAB8A (phospho T72) [MJF-R20] WB, Dot blot Mo, Hu ab230260
Anti-RAB10 (phospho T73) [MJF-R21] WB, Dot blot Mo, Hu ab230261

 

About Abcam

Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.

Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jun 6, 2019 at 9:15 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Abcam. (2019, June 06). Antibodies for Parkinson's Disease Targets. News-Medical. Retrieved on September 23, 2019 from https://www.news-medical.net/whitepaper/20190606/Antibodies-for-Parkinsons-Disease-Targets.aspx.

  • MLA

    Abcam. "Antibodies for Parkinson's Disease Targets". News-Medical. 23 September 2019. <https://www.news-medical.net/whitepaper/20190606/Antibodies-for-Parkinsons-Disease-Targets.aspx>.

  • Chicago

    Abcam. "Antibodies for Parkinson's Disease Targets". News-Medical. https://www.news-medical.net/whitepaper/20190606/Antibodies-for-Parkinsons-Disease-Targets.aspx. (accessed September 23, 2019).

  • Harvard

    Abcam. 2019. Antibodies for Parkinson's Disease Targets. News-Medical, viewed 23 September 2019, https://www.news-medical.net/whitepaper/20190606/Antibodies-for-Parkinsons-Disease-Targets.aspx.

Other White Papers by this Supplier